## SUPPORTING INFORMATION

# Anti-PEG Antibodies Boosted in Humans by SARS-CoV-2 Lipid Nanoparticle mRNA Vaccine

Yi Ju,<sup>1,2,3\*</sup> Wen Shi Lee,<sup>1</sup> Emily H. Pilkington,<sup>1,4</sup> Hannah G. Kelly,<sup>1</sup> Shiyao Li,<sup>3</sup> Kevin J. Selva,<sup>1</sup>
Kathleen M. Wragg,<sup>1</sup> Kanta Subbarao,<sup>1,5</sup> Thi H.O. Nguyen,<sup>1</sup> Louise C. Rowntree,<sup>1</sup> Lilith F.
Allen,<sup>1</sup> Katherine Bond,<sup>6</sup> Deborah A. Williamson,<sup>1,6</sup> Nghia P. Truong,<sup>1,4</sup> Magdalena Plebanski,<sup>2</sup>
Katherine Kedzierska,<sup>1</sup> Siddhartha Mahanty,<sup>7</sup> Amy W. Chung,<sup>1</sup> Frank Caruso,<sup>3</sup> Adam K.

Wheatley, <sup>1</sup> Jennifer A. Juno, <sup>1</sup> Stephen J. Kent<sup>1,8\*</sup>

<sup>1</sup>Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia

<sup>2</sup>School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia

<sup>3</sup>Department of Chemical Engineering, The University of Melbourne, Melbourne, VIC 3000,

#### Australia

<sup>4</sup>Department of Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC 3000, Australia

<sup>5</sup>WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia <sup>6</sup>Department of Microbiology, Royal Melbourne Hospital, Melbourne, VIC 3000, Australia
<sup>7</sup>Department of Infectious Diseases, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia

<sup>8</sup>Melbourne Sexual Health Centre and Department of Infectious Diseases, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC 3000, Australia

\*Corresponding authors. E-mail: david.ju@rmit.edu.au; skent@unimelb.edu.au

#### **BNT162b2** Vaccination



**Figure S1.** Plasma anti-PEG IgG and IgM titres before vaccination (Pre-Vax) and 2 to 7 weeks (mean 27 days, range 12–49) following second dose (Post-Boost) of BNT162b2 vaccination of 55 healthy subjects across 3 separate cohorts. Data are shown as mean of two independent measurements.

### mRNA-1273 Vaccination



**Figure S2.** Plasma anti-PEG IgG and IgM titres before vaccination (Pre-Vax) and 3 weeks (mean 19 days, range 18–27) following second dose (Post-Boost) of mRNA-1273 vaccination of 20 healthy subjects. Data are shown as mean of two independent measurements.

**Unvaccinated Control** 



**Figure S3.** Plasma anti-PEG IgG and IgM titres at baseline and after a 6-month (mean 186 days, range 120–253) period of unvaccinated control cohorts (total n=55, including SARS-CoV-2 infected convalescent patients n=40 and uninfected healthy donors n=15). Data are shown as mean of two independent measurements.

















Figure S4. Time course of PEG antibodies following BNT162b2 vaccination. A) Longitudinal comparison of plasma Anti-PEG IgG and IgM titres in BNT162b2 Cohort 1 subjects (n=17) receiving two doses of the BNT162b2 vaccine at 0-7 days pre-vaccination (Pre-Vax), day 7 post prime, day 7 and 14 post boost. Donor 17's data is excluded due to missing the two middle time points. Data are shown as mean of two independent measurements. p-values were derived by nonparametric Friedman's test with Dunn's multiple comparisons test. B) Longitudinal comparison of plasma Anti-PEG IgG and IgM titres in BNT162b2 Cohort 3 subjects (n=24) receiving two doses of the BNT162b2 vaccine at 0-4 weeks pre-vaccination (Pre-Vax), 3-week (average 22 days, range 14–34) post prime, 1-month (average 33 days, range 22–49) and 3-month (average 85 days, range 74-98) post boost. The 3-month post-boost time points were only collected from 10 subjects (donor 32-41). Data are shown as mean of two independent measurements. p-values comparing between Pre-Vax and 3-Week Post-Prime or 1-Month Post-Boost were derived by nonparametric Friedman's test with Dunn's multiple comparisons test. pvalues comparing between 1-Month Post-Boost and 3-Month post-Boost were derived by Wilcoxon's matched-pairs signed rank test.



**Figure S5**. Gating strategy used to identify white blood cell populations. A) Flow cytometry gating strategy used to identify different immune cell populations from human blood. Forward and side scattering was used to locate white blood cells, followed by excluding doublets. The following cell types were identified based on the expression of surface markers: CD45+ leukocytes, CD66b+ granulocytes, CD14+ monocytes, CD3+ T cells, CD19+ B cells, CD56+ NK cells, and Lin-HLA-DR+ dendritic cells. B) The percentage of each cell type positive for the fluorescence-labelled nanoparticles was then measured as the cell association (%). The representative gating strategy and cell association percentages for each cell type is shown.



**Figure S6.** (A-C) The impact of plasma collected before vaccination (Pre-Vax) and post-boost of the mRNA-1273 vaccination (n=20, donor 56–75) on Onpattro LNP association with (A) granulocytes, (B) monocytes, or (C) B cells in human blood. Onpattro LNP were preincubated in plasma from donor 56–75 collected Pre-Vax or Post-Boost of the mRNA-1273 vaccination, followed by incubation with washed blood cells from donor 16 in serum-free media. Cell

association (%) refers to the proportion of each cell type with positive fluorescence, above background, stemming from fluorescence-labeled particles. Data are shown as the mean  $\pm$  standard deviation (SD) of three independent experiments (using the same batch of plasma from each donor), with at least 150,000 leukocytes analyzed for each experimental condition studied.



**Figure S7.** (A-C) The impact of plasma collected before vaccination (Pre-Vax) and post-boost of the BNT162b2 vaccination (n=18, donor 1–18) on Doxil association with (A) granulocytes, (B) monocytes, or (C) B cells in human blood. Doxil were preincubated in plasma from donor 1–18 collected Pre-Vax or Post-Boost of the BNT162b2 vaccination, followed by incubation with washed blood cells from donor 16 in serum-free media. Cell association (%) refers to the

proportion of each cell type with positive fluorescence, above background, stemming from fluorescence-labeled particles. Data are shown as the mean  $\pm$  SD of three independent experiments (using the same batch of plasma from each donor), with at least 150,000 leukocytes analyzed for each experimental condition studied.



**Figure S8.** (A-C) The impact of plasma collected before vaccination (Pre-Vax) and post-boost of the BNT162b2 vaccination (n=18, donor 1–18) on PEG-MS nanoparticle association with (A) granulocytes, (B) monocytes, or (C) B cells in human blood. PEG-MS nanoparticles were preincubated in plasma from donor 1–18 collected Pre-Vax or Post-Boost of the BNT162b2 vaccination, followed by incubation with washed blood cells from donor 16 in serum-free media.

Cell association (%) refers to the proportion of each cell type with positive fluorescence, above background, stemming from fluorescence-labeled particles. Data are shown as the mean  $\pm$  SD of three independent experiments (using the same batch of plasma from each donor), with at least 150,000 leukocytes analyzed for each experimental condition studied.



**Figure S9.** Impact of pre-existing anti-PEG antibody levels on the association of Doxil with immune cells in human blood. A,B) Spearman correlation between pre-existing (Pre-Vax) anti-PEG IgG or IgM titres (n=18, donor 1–18 from BNT162b2 vaccinee cohort) and Doxil association with monocytes, granulocytes, or B cells in human blood. Cell association (%) refers to the proportion of each cell type with positive fluorescence, above background, stemming from fluorescence-labeled particles. Cell association (%) data are shown as the mean of three

independent experiments (using the same batch of plasma from each donor), with at least 150,000 leukocytes analyzed for each experimental condition studied (see raw data in Figure S7).



**Figure S10.** Impact of change in anti-PEG antibody after BNT162b2 vaccination on the association of Doxil with immune cells in human blood. A) Comparing the impact of plasma collected before vaccination (Pre-Vax) and post-boost of the BNT162b2 vaccination (n=18, donor 1–18) on Doxil association with monocytes, granulocytes, or B cells in human blood. p-values were derived by Wilcoxon's matched-pairs signed rank test. B) Spearman correlation between the fold change (log<sub>10</sub>) of anti-PEG IgG or IgM titres (Post-Boost/Pre-Vax) after 2 doses of BNT162b2 vaccination (n=18, donor 1–18) and change in Doxil association with monocytes, granulocytes, or B cells in human blood. Cell association (%) refers to the proportion of each cell type with positive fluorescence, above background, stemming from fluorescence-labeled particles. Cell association (%) data are shown as the mean of three independent experiments (using the same batch of plasma from each donor), with at least 150,000 leukocytes analyzed for each experimental condition studied (see raw data in Figure S7). Change in cell association (%) refers to post-boost cell association (%) minus pre-vax cell association (%).



**Figure S11.** Impact of pre-existing anti-PEG antibody levels on the association of PEG-MS nanoparticles with immune cells in human blood. A,B) Spearman correlation between pre-existing (Pre-Vax) anti-PEG IgG or IgM titres (n=18, donor 1–18 from BNT162b2 vaccinee cohort) and PEG-MS nanoparticle association with monocytes, granulocytes, or B cells in human blood. Cell association (%) refers to the proportion of each cell type with positive fluorescence, above background, stemming from fluorescence-labeled particles. Cell association (%) data are shown as the mean of three independent experiments (using the same batch of plasma from each donor),

with at least 150,000 leukocytes analyzed for each experimental condition studied (see raw data in Figure S8).



**Figure S12.** Impact of change in anti-PEG antibody after BNT162b2 vaccination on the association of PEG-MS nanoparticles with immune cells in human blood. A) Comparing the impact of plasma collected before vaccination (Pre-Vax) and post-boost of the BNT162b2 vaccination (n=18, donor 1–18) on PEG-MS nanoparticle association with monocytes, granulocytes, or B cells in human blood. p-values were derived by Wilcoxon's matched-pairs signed rank test. B) Spearman correlation between the fold change (log<sub>10</sub>) of anti-PEG IgG or IgM titres (Post-Boost/Pre-Vax) after 2 doses of BNT162b2 vaccination (n=18, donor 1–18) and change in PEG-MS nanoparticle association with monocytes, granulocytes, or B cells in human blood. Cell association (%) refers to the proportion of each cell type with positive fluorescence, above background, stemming from fluorescence-labeled particles. Cell association (%) data are shown as the mean of three independent experiments (using the same batch of plasma from each donor), with at least 150,000 leukocytes analyzed for each experimental condition studied (see raw data in Figure S8). Change in cell association (%) refers to post-boost cell association (%) minus pre-vax cell association (%).



**Figure S13**. ELISA absorbance showing the PEG-specific antibody-mediated C1q binding of plasma collected before vaccination (Pre-Vax) and post-boost of the mRNA-1273 vaccination (n=20, donor 56–75). The ELISA were performed by coating 40kDa PEG on ELISA plates and the plasma were diluted at 1:5 in 1% BSA, followed by washing and incubating with Horseradish peroxidase (HRP)-conjugated C1q. No PEG-precoating wells were used as background. Data are shown as mean of two independent measurements.



**Figure S14**. The impact of PEG specific antibody on neutralizing antibody responses. A) Spearman correlation between live SARS-COV-2 neutralization titre (inhibitory dilution 50, ID<sub>50</sub>) of post-boost plasma (donor 1-55 from BNT162b2 vaccinee cohort) and the fold change (log<sub>10</sub>) of anti-PEG IgG or IgM titres (Post-Boost/Pre-Vax) after 2 dose of BNT162b2 vaccination (n=55, donor 1–55). B) Spearman correlation between live SARS-COV-2 neutralization titre (inhibitory dilution 50, ID<sub>50</sub>) of post-boost plasma (donor 1-55 from BNT162b2 vaccinee cohort) and the pre-existing (Pre-Vax) anti-PEG IgG or IgM titres (n=55, donor 1–55 from BNT162b2 vaccinee cohort) and the pre-existing (Pre-Vax) anti-PEG IgG or IgM titres (n=55, donor 1–55 from BNT162b2 vaccinee cohort). C) Spearman correlation between live SARS-COV-2 neutralization titre (inhibitory dilution 50, ID<sub>50</sub>) of post-boost plasma (donor 1-55 from BNT162b2 vaccinee cohort) and the post-boost anti-PEG IgG or IgM titres (n=55, donor 1–55 from BNT162b2 vaccinee cohort) and the post-boost anti-PEG IgG or IgM titres (n=55, donor 1–55 from BNT162b2 vaccinee cohort).

Donor ID	Cohort ID	Sex	Age range	Days between two doses	Days post second dose sample collected <sup>a</sup>				
1	1	F	51-55	22	12				
2	1	М	26-30	23	13				
3	1	F	26-30	22	13				
4	1	F	21-25	21	13				
5	1	М	31-35	27	14				
6	1	F	31-35	28	13				
7	1	F	31-35	21	13				
8	1	F	26-30	26-30 29					
9	1	F	26-30	26-30 24					
10	1	F	21-25	33	14				
11	1	М	31-35	22	13				
12	1	F	36-40	22	13				
13	1	М	26-30	23	15				
14	1	F	56-40	22	13				
15	1	F	31-35	31-35 23					
16	1	М	31-35	31-35 21					
17	1	F	41-45	25	14				
18	1	М	26-30	21	14				
19	2	F	21-25	24	34				
20	2	F	36-40	24	34				
21	2	F	26-30	30	35				
22	2	М	41-45	28	43				
23	2	М	46-50	28	37				
24	2	М	26-30	24	34				
25	2	F	21-25	24	34				
26	2	F	31-35	24	34				
27	2	М	56-60	19	38				
28	2	F	36-40	27	36				
29	2	F	46-50	28	36				
30	2	F	51-55	24	28				
31	2	F	26-30	28	36				
32	3	F	61-65	26	26/74				
33	3	М	61-65	27	33/75				
34	3	М	26-30	24	35/77				
35	3	F	36-40	25	34/90				
36	3	М	41-45	19	25/81				
37	3	F	61-65	24	40/89				
38	3	F	26-30	22	26/89				
39	3	М	21-25	29	42/98				
40	3	М	61-65	28	41/90				

 Table S1. BNT162b2 Vaccinee information

41	3	М	46-50	25	28/90			
42	3	F	31-35	30	27			
43	3	Μ	61-65	26	26			
44	3	F	26-30	31	34			
45	3	F	41-45	22	27			
46	3	F	36-40	22	28			
47	3	F	31-35	35	33			
48	3	F	36-40	17	49			
49	3	М	46-50	21	49			
50	3	F	36-40	30	26			
51	3	F	36-40	22	32			
52	3	М	46-50	31	22			
53	3	F	46-50	23	40			
54	3	М	31-35	22	31			
55	3	F	26-30	22	30			
		F:			1st time point: Mean 27			
Sum	more	n=35	Mean 38	Mean 25 (range	(range 12–49)			
Summary		M:	(range 23–65)	17-35)	2nd time point: Mean 85			
		n=20			(range 74–98)			

<sup>a</sup>Two post-boost time points were collected for donor 32–41, displayed as A/B.

Donor ID	Sex	Age range	Days between two doses	Days post second dose sample collected
56	F	46-50	27	19
57	М	31-35	28	18
58	F	21-25	26	27
59	F	81-85	27	19
60	М	66-70	27	19
61	М	31-35	28	18
62	F	36-40	28	18
63	М	71-75	27	19
64	F	36-40	28	18
65	М	36-40	28	18
66	F	26-30	28	18
67	F	41-45	28	18
68	F	41-45	28	18
69	М	46-50	28	18
70	М	36-40	28	18
71	F	41-45	28	18
72	F	31-35	28	18
73	М	46-50	28	18
74	М	51-55	28	18
75	F	26-30	28	18
Summary	F: n=11 M: n=9	Mean 44 (range 24–84)	Mean 30 (range 26–28)	Mean 19 (range 18–27)

Table S2. mRNA-1273 Vaccinee information

Donor ID	Sex	Age range	Health status <sup>a</sup>	Days in between two samples
76	F	21-25	COVID+	126
77	F	66-70	COVID+	147
78	М	66-70	COVID+	147
79	М	76-80	COVID+	192
80	F	51-55	COVID+	161
81	М	61-65	COVID+	182
82	М	56-60	COVID+	192
83	F	51-55	COVID+	168
84	F	21-25	COVID+	182
85	F	66-70	COVID+	178
86	F	56-60	COVID+	245
87	М	61-65	COVID+	210
88	М	66-70	COVID+	148
89	М	56-60	COVID+	168
90	F	56-60	COVID+	168
91	М	61-65	COVID+	175
92	М	46-50	COVID+	185
93	F	51-55	COVID+	185
94	М	61-65	COVID+	168
95	М	56-60	COVID+	122
96	F	56-60	COVID+	168
97	F	46-50	COVID+	248
98	М	31-35	COVID+	120
99	F	26-30	COVID+	120
100	F	61-65	COVID+	203
101	М	21-25	COVID+	204
102	М	66-70	COVID+	203
103	М	56-60	COVID+	197
104	F	51-55	COVID+	210
105	F	46-50	COVID+	210
106	М	56-60	COVID+	253
107	F	56-60	COVID+	253
108	М	51-55	COVID+	217
109	F	51-55	COVID+	179
110	М	56-60	COVID+	179
111	F	31-35	COVID+	226
112	М	31-35	COVID+	196
113	М	56-60	COVID+	196
114	F	51-55	COVID+	196
115	F	21-25	COVID+	244

-							
116	F	51-55	COVID-	210			
117	М	51-55	COVID-	210			
118	F	56-60	COVID-	189			
119	F	56-60	COVID-	196			
120	F	56-60	COVID-	182			
121	F	56-60	COVID-	182			
122	F	21-25	COVID-	175			
123	F	51-55	COVID-	175			
124	М	51-55	COVID-	189			
125	F	61-65	COVID-	193			
126	F	61-65	COVID-	168			
127	F	61-65	COVID-	168			
128	М	61-65	COVID-	168			
129	М	51-55	COVID-	175			
130	F	51-55	COVID-	189			
	F: n=31	Maan 52 (ranga	COVID+: 40				
Summary	M: n=24	21–76)	COVID-: 15	Mean 186 (range 120–253)			

<sup>a</sup>Donor 76–115 are SARS-CoV-2 infected convalescent subjects (COVID+) and Donor 116–130 are uninfected healthy donors (COVID-).

Particle Type	Size (nm) <sup>a</sup>	Polydispersity Index <sup>a</sup>	Zeta Potential (mV) <sup>b</sup>
PEG-MS nanoparticles	$102 \pm 30$	0.015	$-32 \pm 7$
Doxil	$72 \pm 20$	0.067	-11 ± 9
LNPs	$61 \pm 18$	0.079	$-10 \pm 2$

**Table S4.** Size and zeta potential of PEGylated nanoparticles

<sup>a</sup>The size and polydispersity index were determined by dynamic light scattering using a Zetasizer Nano-ZS (Malvern Instruments, UK) instrument.

<sup>b</sup>Zeta potential measurements were performed at pH 7.4 in phosphate buffer (5mM) using a Zetasizer Nano-ZS (Malvern Instruments, UK) instrument.

	Donor ID:	1	2	3	4	5	6	7	8	9	1 0	1 1	1 2	1 3	1 4	15
ite	Pain	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	Y	Y	Y	Y
on S	Redness	N	N	N	N	Y	N	Y	Ν	Y	N	N	Y	Ν	Ν	Ν
ecti	Swelling	N	N	Ν	N	Y	N	N	N	Y	N	N	Y	Ν	N	Y
Inj	Itching	N	N	N	N	N	N	N	N	N	N	N	N	Ν	Ν	Y
	Fatigue	N	Y	Y	N	N	Y	Y	Y	Y	Y	Y	Y	Ν	Ν	Ν
	Headache	Ν	Ν	Y	Ν	Ν	Ν	Y	Ν	Ν	Y	Y	Ν	Ν	Ν	Y
	Myalgia	Ν	Y	Y	Ν	Ν	Ν	Ν	Y	Ν	Ν	Y	Ν	Ν	Ν	Ν
	Chills	N	Y	Y	N	N	Y	Y	N	N	Y	N	N	Ν	N	Y
ic	Fever	Ν	Ν	Y	Ν	N	Ν	N	Ν	N	Ν	N	N	Ν	Ν	Y
tem	Joint pain	Ν	Y	Y	N	N	Ν	N	Ν	N	N	N	N	Ν	Ν	Ν
Sys	Nausea	Ν	Ν	Ν	Ν	N	N	Ν	N	Ν	Ν	Y	N	Ν	Ν	N
	Vomiting	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν
	Diarrhea	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν
	Abdominal Pain	Ν	Ν	Ν	Ν	Ν	Y	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν
	Rash (non-injection	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
L	Local Reactogenicity Score		1	1	1	3	1	2	1	3	0	1	3	1	1	3
Sys	temic Reactogenicity Score	0	4	6	0	0	3	3	2	1	3	4	1	0	0	3
Т	otal Reactogenicity Score	1	5	7	1	3	4	5	3	4	3	5	4	1	1	6
	Donor ID:	1 6	1 7	1 8	1 9	2 0	2 1	2 2	2 3	2 4	2 5	2 6	2 7	2 8	2 9	30
lite	Pain	Ν	Ν	Y	Ν	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Ν
on S	Redness	Ν	Ν	Ν	Y	Ν	Ν	Y	Y	Y	Y	Y	Y	Y	Y	Ν
ecti	Swelling	Y	Ν	Y	Y	N	Ν	Ν	Ν	Ν	Ν	Ν	N	Ν	Ν	N
Inj	Itching	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν
	Fatigue	Y	Y	Y	Ν	N	Ν	Y	N	Y	Y	Y	Y	Ν	Ν	N
nic	Headache	Y	Ν	Y	Ν	N	Y	N	N	N	Ν	Y	Ν	Ν	Y	N
sten	Myalgia	Y	Ν	Y	N	N	Y	Ν	N	Y	Y	Ν	Y	Ν	Ν	N
Sy	Chills	Ν	Ν	Y	Ν	N	Ν	Ν	N	N	Ν	Ν	Ν	Ν	Ν	N
	Fever	Y	Y	Y	Ν	Y	Ν	Ν	Y	Ν	Ν	Y	Ν	Ν	Ν	N

 Table S5. Reported reactogenicity after boost of BNT162b2 vaccination from 44 donors

	Joint pain	Y	N	N	N	N	N	Ν	Ν	N	Y	N	Y	Ν	N	N
	Nausea	N	N	N	N	Y	N	N	N	N	Y	N	N	N	N	Ν
	Vomiting	N	N	N	N	N	N	N	N	N	N	N	N	N	N	Ν
	Diarrhea	N	N	N	N	Ν	N	N	N	N	N	N	N	N	N	Ν
	Abdominal Pain	N	N	N	N	Ν	N	N	N	N	N	N	N	N	N	Ν
	Rash (non-injection site)	N	N	N	N	N	N	N	N	N	N	N	N	N	N	N
L	ocal Reactogenicity Score	1	0	2	2	1	1	2	2	2	2	2	2	2	2	0
Sys	temic Reactogenicity Score	5	2	5	0	2	2	1	1	2	4	3	3	0	1	0
Т	otal Reactogenicity Score	6	2	7	2	3	3	3	3	4	6	5	5	2	3	0
	Donor ID:	3 1	3 2	3 3	4 0	4 1	4 2	4 3	4 5	4 7	5 0	5 1	5 3	5 4	5 5	
lite	Pain	Ν	Y	Y	Ν	Ν	Y	Y	Y	Ν	Ν	Y	N	Y	Ν	
on S	Redness	Ν	Ν	Ν	Ν	Ν	N	Y	Y	Ν	Ν	N	N	Ν	Ν	
ecti	Swelling	Ν	Ν	Ν	Ν	Ν	N	Ν	Y	Ν	Ν	N	N	Ν	Ν	
Inj	Itching	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Y	Ν	Ν	Ν	Ν	Ν	Ν	
	Fatigue	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Y	Ν	Ν	Ν	Y	Ν	Y	
	Headache	N	N	N	Y	Ν	Y	Ν	Y	N	N	N	N	Ν	Y	
	Myalgia	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Y	Ν	Y	
	Chills	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Y	Ν	Y	
ic	Fever	N	N	N	N	Ν	Ν	Ν	Ν	N	N	N	N	Ν	Y	
tem	Joint pain	N	N	N	N	Ν	N	Ν	Ν	N	N	N	Y	Ν	Ν	
Sys	Nausea	Ν	Ν	Ν	N	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Y	
	Vomiting	N	N	N	N	Ν	N	Ν	Ν	N	N	N	N	Ν	Ν	
	Diarrhea	N	N	N	N	N	N	Y	Ν	N	N	N	N	Ν	Ν	
	Abdominal Pain	Ν	N	Ν	Ν	Ν	N	Ν	Ν	Ν	Ν	Ν	Ν	Ν	Ν	
	Rash (non-injection site)	N	N	N	N	N	N	N	N	N	N	N	N	N	N	Mea n
L	ocal Reactogenicity Score	0	1	1	0	0	1	2	4	0	0	1	0	1	0	1.3
Sys	temic Reactogenicity Score	0	0	0	1	0	1	1	2	0	0	0	4	0	6	1.7
Т	otal Reactogenicity Score	0	1	1	1	0	2	3	6	0	0	1	4	1	6	3.0

	Donor ID:	56	57	58	59	60	61	62	63	64	65
ite	Pain	Y	Y	Y	Y	Y	Y	Y	N	Y	Ν
on S	Redness	Y	N	Ν	N	N	Ν	Ν	N	Ν	Y
ecti	Swelling	Y	N	Y	Ν	Ν	Y	Ν	Ν	Ν	Ν
Inj	Itching	N	N	N	N	N	Y	N	N	Ν	N
	Fatigue	Y	Y	N	N	Y	N	Y	N	Y	N
	Headache	Y	N	Y	N	Y	N	Y	N	Ν	Ν
	Myalgia	Y	Y	Ν	N	Y	Y	Ν	N	Y	Y
	Chills	Y	N	Y	N	N	N	Y	N	Y	Y
.e Fever		Y	N	Y	N	N	N	Y	N	Y	Y
sten	Joint pain	Y	Y	Y	N	Y	N	N	N	N	Y
Sy	Nausea	Y	N	N	N	N	N	Y	N	Ν	N
	Vomiting	N	N	Ν	N	N	N	N	N	Ν	Ν
	Diarrhea	N	N	Y	N	N	N	N	N	N	Ν
	Abdominal Pain	N	N	N	N	N	N	Y	N	N	N
	Rash (non-injection site)	N	N	N	N	N	N	N	N	N	N
Local Reactogenicity Score		3	1	2	1	1	3	1	0	1	1
Sy	stemic Reactogenicity Score	7	3	5	0	4	1	6	0	4	4
1	Total Reactogenicity Score	10	4	7	1	5	4	7	0	5	5
	Donor ID:	66	67	68	69	70	71	73	74	75	
Site	Pain	Ν	Y	Y	Y	Y	Y	Y	Y	Y	
on S	Redness	Ν	Ν	Y	Ν	Ν	Ν	Ν	Ν	Y	
ecti	Swelling	N	N	Y	Y	Ν	Ν	Ν	Ν	Ν	
Inj	Itching	N	N	Ν	N	N	N	Ν	N	Ν	
	Fatigue	N	Y	Y	Y	Y	Y	Y	Y	Y	
	Headache	N	Y	Y	Ν	Y	Y	Y	Y	Y	
ల	Myalgia	N	Y	Y	Y     Y     Y     N     Y       N     N     N     N     N     N       N     N     Y     N     N     N       N     N     Y     N     N     N       N     Y     N     Y     N     Y       N     Y     N     Y     N     Y       N     Y     N     Y     N     Y       N     Y     N     Y     N     Y       N     Y     N     Y     N     Y       N     Y     N     Y     N     Y       N     N     N     Y     N     Y       N     N     N     N     N     N       N     N     N     N     N     N       N     N     N     N     N     N       N     N     N     N     N     N       N     N     N     N     N     N       N     N     N     N     N     N       N     N     N     N     N     N       N     N     N     N     N     N       Y     Y     Y     Y <td></td>						
emi	Chills	N	N	Y	Y	Y	Y	Y	Y	Y	
Syst	Fever	N	N	Y	Ν	Y	Ν	Y	Y	Ν	
	Joint pain	N	Y	Ν	Y	Y	Y	Y	N	Y	
	Nausea	N	N	N	N	N	Y	N	Y	Y	
	Vomiting	Ν	Ν	Ν	Ν	Ν	Y	Ν	Ν	N	

Table S6. Reported reactogenicity after boost of mRNA-1273 vaccination from 19 donors

	Diarrhea	N	N	N	N	N	Y	N	N	N	
	Abdominal Pain	N	N	N	N	N	Y	N	N	N	
	Rash (non-injection site)	N	N	N	N	Ν	N	N	N	N	Mean
	Local Reactogenicity Score	0	1	3	2	1	1	1	1	2	1.4
Sy	ystemic Reactogenicity Score	0	4	5	4	6	9	6	6	6	4.2
	Total Reactogenicity Score	0	5	8	6	7	10	7	7	8	5.6